news New imaging technique may predict the of spread breast cancer 16 August 2017 | By Dr Zara Kassam (Drug Target Review) Researchers have developed a radioactive ‘tracer’ molecule to detect myeloid-derived suppressor cells’ accumulating in the lung in preparation for the arrival of breast cancer cells...
news Novel immuno-oncology treatment for patients with advanced solid tumours 10 August 2017 | By Dr Zara Kassam (Drug Target Review) An experimental immuno-oncology treatment will move into early phase clinical trials for patients with advanced solid tumours...
news Power of radiomics to improve precision medicine 4 August 2017 | By Dr Zara Kassam (Drug Target Review) Data mining of medical images with radiomics offers clinicians a way to characterise lung tumours and improve precision medicine...
news Largest genome-wide study of lung cancer susceptibility conducted 13 July 2017 | By Niamh Marriott (Drug Target Review) A new study conducted by an international team of lung cancer researchers have identified new genetic variants for lung cancer risk.
news Lung cancer screening could save money as well as lives, research shows 6 July 2017 | By Niamh Marriott (Drug Target Review) Lung cancer screening is likely to be cost-effective, particularly if it also identifies other tobacco-related conditions in high-risk people, suggests new research.
news Tracking unstable chromosomes helps predict lung cancer’s return 27 April 2017 | By Niamh Marriott (Drug Target Review) Scientists have found that unstable chromosomes within lung tumours increases the risk of cancer returning after surgery, and have used this new knowledge to detect relapse long before standard testing.
news £2.5 million Cancer Research UK collaboration to target ‘undruggable’ RAS 19 April 2017 | By Niamh Marriott (Drug Target Review) Scientists will develop and test promising new molecules for targeting RAS, one of the most common driving mutations in aggressive, hard to treat cancers including pancreatic and lung cancer.
news Stem cell ‘marking’ study offers alternative hypothesis of cancer metastasis 24 February 2017 | By Niamh Marriott (Drug Target Review) Stem cells are among the most energetically activated, migratory and proliferative sub-populations of tumour cells, according to observations by scholars at the Biomedical Research Centre at the University of Salford.
news AbbVie and Bristol-Myers Squibb announce lung cancer clinical trials collaboration 25 July 2016 | By Niamh Louise Marriott, Digital Content Producer AbbVie and Bristol-Myers Squibb Company today announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie’s investigational biomarker-specific antibody drug conjugate Rova-T...
article Advancing FLIP inhibitors for the treatment of NSCLC 26 April 2016 | By Victoria White, Drug Target Review In an exclusive interview, Trevor Perrior, Research Director at Domainex, discusses the cell death regulatory protein FLIP and the potential of FLIP inhibitors as a treatment for NSCLC...
news Queen’s University Belfast and Domainex secure award to advance FLIP inhibitor 26 April 2016 | By Victoria White, Digital Content Producer Queen’s University Belfast and Domainex have secured an award to advance therapeutic candidate molecules into clinical evaluation for treatment of NSCLC...
news Epiregulin identified as a possible target in lung cancer 8 April 2016 | By Victoria White, Digital Content Producer A study found that in addition to decreased overall tumour burden, mice lacking epiregulin also showed reduced inflammation...
news Researchers find new genetic target for NSCLC 23 March 2016 | By Victoria White Researchers have identified mutations in NSCLC that are key to tumour growth, offering a new way to differentiate patients with the disease...
news Blueprint Medicines announces first preclinical data for BLU6864 23 June 2015 | By Victoria White Blueprint Medicines has announced the first preclinical data for its drug candidate BLU6864, a RET-specific kinase inhibitor.
